VTRS · 8-K · 20260806PR000037
Distribution Channels and Partnerships
Viatris Inc · 2026-08-06 · Importance 31 · Surprise 42 · In source text
Viatris signed a distribution agreement with Accord Healthcare to commercialize filgrastim, ustekinumab and teriparatide biosimilars in France. The company also entered a co-promotion partnership with Idorsia for Quviviq in Italy and Canada. These arrangements use regional commercial partners to expand access to biosimilars and branded products across European and North American markets. The disclosed agreements broaden Viatris’s indirect distribution and co-promotion reach without describing a change in direct-channel or e-commerce mix.
Key facts
- The Company signed a distribution agreement with Accord Healthcare to commercialize three biosimilar products (filgrastim, ustekinumab, teriparatide) in France source
- The Company signed a co-promotion partnership with Idorsia Ltd. for Quviviq in Italy and Canada source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | The Company signed a distribution agreement with Accord Healthcare to commercialize three biosimilar products (filgrastim, ustekinumab,… |
| revenue | positive | committed | — | The Company signed a co-promotion partnership with Idorsia Ltd. for Quviviq in Italy and Canada |